Approval provides Japanese recurrent glioblastoma patients with a new, effective and safe treatment option ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Optune™, a Tumor Treating Fields (TTFields) delivery device, for the treatment of patients with recurrent glioblastoma (GBM). “This …